$-0.37 EPS Expected for vTv Therapeutics Inc. (VTVT)

April 21, 2018 - By Michael Collier

Analysts expect vTv Therapeutics Inc. (NASDAQ:VTVT) to report $-0.37 EPS on May, 2.They anticipate $0.07 EPS change or 15.91 % from last quarter’s $-0.44 EPS. After having $-0.44 EPS previously, vTv Therapeutics Inc.’s analysts see -15.91 % EPS growth. The stock decreased 1.19% or $0.025 during the last trading session, reaching $2.085. About 3.35M shares traded or 176.26% up from the average. vTv Therapeutics Inc. (NASDAQ:VTVT) has declined 34.95% since April 21, 2017 and is downtrending. It has underperformed by 46.50% the S&P500.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company has market cap of $68.41 million. The company's drug candidate for the treatment of Alzheimer's disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. It currently has negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.

vTv Therapeutics Inc. (NASDAQ:VTVT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: